<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2406200100
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2020
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Takhzyro
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        LANADELUMAB
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        300
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Subcutaneous use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Solution for injection
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        2
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        1
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Vial
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Biological
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store in a refrigerator (2°c – 8°c)
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        52774.45
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Catalent Indiana LLC formerly Cook Pharmica LLC" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Catalent Indiana LLC formerly Cook Pharmica LLC
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 612]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            Abdulrehman Algosaibi G.T.C.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Takeda Pharmaceuticals International AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>TAKHZYRO contains the active substance lanadelumab.</p><p><strong>What TAKHZYRO is used for</strong></p><p>TAKHZYRO is a medicine used in adults, and adolescents aged 12 years and older to prevent angioedema attacks, in patients with HAE.</p><p><strong>What hereditary angioedema (HAE) is</strong></p><p>HAE is a condition which runs in families. With this condition your blood does not have enough of a protein called &lsquo;C1 inhibitor&rsquo;, or C1 inhibitor does not work properly. This leads to too much &lsquo;plasma kallikrein&rsquo;, which in turn produces higher levels of &lsquo;bradykinin&rsquo; in your bloodstream. Too much bradykinin leads to symptoms of HAE like swelling and pain on the,</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; hands and feet</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; face, eyelids, lips or tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; voice-box (larynx), which may make breathing difficult</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; genitals</p><p><strong>How TAKHZYRO works</strong></p><p>TAKHZYRO is a type of protein that blocks the activity of plasma kallikrein. This helps to reduce the amount of bradykinin in your bloodstream and prevents symptoms of HAE.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Do not use TAKHZYRO:</strong></p><p>If you are allergic to lanadelumab or any of the other ingredients of this medicine (listed in section 6).</p><p><strong>Warnings and precautions</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Talk to your doctor, pharmacist or nurse before using TAKHZYRO.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have a severe allergic reaction to TAKHZYRO with symptoms such as a rash, a tight chest, wheezing, or a fast heart beat, tell your doctor, pharmacist or nurse <strong>immediately.</strong></p><p><strong>Keeping a record</strong></p><p>It is strongly recommended that every time you have a dose of TAKHZYRO, you write down the name and batch number of the medicine. This is so that you keep a record of the batches used.</p><p><strong>Laboratory tests</strong></p><p>Tell your doctor if you are using TAKHZYRO before you have laboratory tests to measure how well your blood is clotting. This is because TAKHZYRO in the blood may interfere with some laboratory tests, leading to inaccurate results</p><p><strong>Children and adolescents</strong></p><p>TAKHZYRO is not recommended for use in children under 12 years of age. This is because it has not been studied in this age group.</p><p><strong>Other medicines and TAKHZYRO</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines. TAKHZYRO is not known to affect other medicines or be affected by other medicines.</p><p><strong>Pregnancy and breast-feeding</strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before starting to use Takhzryo. There is limited information on the safety of TAKHZYRO use during pregnancy and breast-feeding. As a precautionary measure, it is preferable to avoid the use of lanadelumab during pregnancy and breast-feeding. Your doctor will discuss with you the risks and benefits of taking this medicine.</p><p><strong>Driving and using machines</strong></p><p>This medicine has negligible influence on the ability to drive or use machines.</p><p><strong>TAKHZYRO contains sodium</strong></p><p>The medicine contains less than 1 mmol sodium (23 mg) per ml of solution, that is to say essentially &lsquo;sodium-free&rsquo;.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>TAKHZYRO is provided in single-use vials as ready-to-use solution. Your treatment will be started and managed under the supervision of a doctor experienced in the care of patients with HAE.</p><p>Always use this medicine exactly as described in this leaflet or as your doctor, pharmacist or nurse has told you. Check with your doctor, pharmacist or nurse if you are not sure or have any further questions on the use of this medicine.</p><p><strong>How much TAKHZYRO to use</strong></p><p>The recommended starting dose is 300 mg every 2 weeks. If you have not had an attack for a long period, your doctor may change the dose to 300 mg every 4 weeks, especially if you have a low body weight.</p><p><strong>How to inject TAKHZYRO</strong></p><p><strong>If you inject TAKHZYRO yourself or if your caregiver injects it, you or your caregiver must carefully read and follow the instructions in section 7, &ldquo;Instructions for use&rdquo;.</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; TAKHZYRO is for injection under the skin (&lsquo;subcutaneous injection&rsquo;).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The injection can be given either by yourself or a caregiver.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; A doctor, pharmacist or nurse should show you how to prepare and inject TAKHZYRO properly before you use it for the first time. Do not inject yourself or someone else until you have been trained to inject the medicine.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Insert the needle into the fatty tissue in the tummy (abdomen), thigh or upper arm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Inject the medicine in a different place each time.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Use each vial of TAKHZYRO only once.</p><p><strong>If you use more TAKHZYRO than you should</strong></p><p>Tell your doctor, pharmacist or nurse if you take too much TAKHZYRO.</p><p><strong>If you forget to use TAKHZYRO</strong></p><p>If you miss a dose of TAKHZYRO, inject your dose as soon as possible but there must be at least 10 days between each dose. If you are not sure when to inject TAKHZYRO after a missed dose, ask your doctor, pharmacist or nurse.</p><p><strong>If you stop using TAKHZYRO</strong></p><p>It is important that you keep injecting TAKHZYRO as instructed by your doctor even if you feel better. If you have any further questions on the use of this medicine, ask your doctor, pharmacist or nurse.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p>If you have a severe allergic reaction to TAKHZYRO with symptoms such as a rash, tight chest, wheezing, or a fast heart beat, tell your doctor, pharmacist or nurse <strong>immediately.</strong></p><p>Tell your doctor, pharmacist or nurse if you notice any of the following side effects.</p><p><strong>Very common (may affect more than 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Reactions where the injection is given &ndash; symptoms include pain, skin redness, bruising, discomfort, swelling, bleeding, itching, hardening of skin, tingling, warmth and rash.</p><p><strong>Common (may affect up to 1 in 10 people):</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions including itching, discomfort and tingling of the tongue</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Dizziness, feeling faint</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Raised skin rash</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Muscle pain</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Blood tests showing liver changes</p><p>Reporting of side effects</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Saudi Arabia:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>-&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Fax: +966-11-205-7662</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p></td></tr></tbody></table><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Other GCC States:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p>- Please contact the relevant competent authority.</p></td></tr></tbody></table><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.</p><p>Do not use this medicine after the expiry date which is stated on the label after EXP. The expiry date refers to the last day of that month.</p><p>Store in a refrigerator (2&deg;C-8&deg;C). Do not freeze. Keep the vial in the outer carton in order to protect from light.</p><p>Vials may be stored below 25&deg;C for a single period of 14 days, but not beyond the expiry date. Do not return TAKHZYRO to refrigerated storage after storage at room temperature.</p><p>Do not use this medicine if you notice signs of deterioration such as particles in the vial or changed colour of the injection solution.</p><p>Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The active substance is lanadelumab. Each vial contains 300 mg of lanadelumab in 2mL.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The other ingredients are disodium phosphate dihydrate, citric acid monohydrate, histidine, sodium chloride, polysorbate 80 and water for injections &ndash; see section 2 &ldquo;TAKHZYRO contains sodium&rdquo;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                TAKHZYRO is presented as a clear, colourless to slightly yellow solution for injection in a glass vial. TAKHZYRO is available as a single pack containing a 2 ml vial.
Each pack also contains the following items:

•	Empty 3 ml syringe
•	18 gauge blunt tip vial access needle
•	27 gauge ½ inch (0.4 x 13 mm) pointed tip administration (injection) needle.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Shire Pharmaceuticals Ireland Limited Blocks 2 &amp; 3 Miesian Plaza</p><p>50-58 Baggot Street Lower Dublin 2</p><p>IRELAND</p><p>Tel: +44(0)1256 894 959</p><p>E-mail: medinfoEMEA@shire.com</p><p>Manufacturer:</p><p>Catalent Indiana, LLC &ndash; USA</p><p>For any information about this medicine, please contact the local representative of the Marketing Authorisation Holder:</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                This leaflet was last revised in 02/2019.


This is a Medicament
-	Medicament is a product which affects your health and its consumption contrary to instructions is dangerous for you.
-	Follow strictly the doctor’s prescription, the method of use and the instructions of the pharmacist who sold the medicament.
-	The doctor and the pharmacist are the experts in medicines, their benefits and risks.
-	Do not by yourself interrupt the period of treatment prescribed for you.
-	Do not repeat the same prescription without consulting your doctor.
-	Keep all medicaments out of reach of children.
Council of Arab Health Ministers Union of Arab Pharmacists
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>ﯾﺣﺗوي ﺗﺎﻛزﯾرو&nbsp;ﻋﻠﻰ اﻟﻣﺎدة اﻟﻔ&nbsp; ّﻌﺎﻟﺔ&nbsp;ﻻﻧﺎدﯾﻠوﻣﺎب.&nbsp;دواﻋﻲ اﺳﺗﺧدام ﺗﺎﻛزﯾرو</p><p dir="RTL">ﯾُﺳﺗﺧدم ﺗﺎﻛزﯾرو ﻣﻊ اﻟﺑﺎﻟﻐﯾن واﻟﻣراھﻘﯾن ﻣن ﻋﻣر 12 ﻋﺎ&nbsp; ًﻣﺎ ﻓﺄﻛﺑر ﻟﻠوﻗﺎﯾﺔ ﻣن ﻧوﺑﺎت اﻟوذﻣﺔ اﻟوﻋﺎﺋﯾﺔ، ﻟدى اﻟﻣرﺿﻰ اﻟذﯾن ﯾﻌﺎﻧون ﻣن اﻟوذﻣﺔ اﻟوﻋﺎﺋﯾﺔ اﻟوراﺛﯾﺔ .(HAE)</p><p><strong>ﻣﺎ ھﻲ اﻟوذﻣﺔ اﻟوﻋﺎﺋﯾﺔ اﻟوراﺛﯾﺔ HAE))؟</strong></p><p dir="RTL">اﻟوذﻣﺔ اﻟوﻋﺎﺋﯾﺔ اﻟوراﺛﯾﺔ (HAE) ھﻲ ﺣﺎﻟﺔ ﻣرﺿﯾﺔ ﺗﺗوارﺛﮭﺎ اﻟﻌﺎﺋﻼت. ﻓﻲ ھذه اﻟﺣﺎﻟﺔ اﻟﻣرﺿﯾﺔ، ﻻ ﯾﺣﺗوي اﻟدم ﻋﻠﻰ ﻣﺎ ﯾﻛﻔﻲ ﻣن ﺑروﺗﯾن ﯾُﺳﻣﻰ &quot;ﻣﺛﺑط ﺳﻲ &quot;1، أو ﻻ ﯾﻌﻣل ﻣﺛﺑط ﺳﻲ 1 ﺑﺷﻛ ٍل ﺳﻠﯾم. ﻣﻣﺎ ﯾؤدي إﻟﻰ وﺟود ﻛﻣﯾﺔ زاﺋدة ﻣن &quot;ﻛﺎﻟﯾﻛرﯾن اﻟﺑﻼزﻣﺎ&quot;، اﻟذي ﯾﻧﺗﺞ ﺑدوره ﻣﺳﺗوﯾﺎت أﻋﻠﻰ ﻣن &quot;ﺑرادﯾﻛﯾﻧﯾن&quot; ﻓﻲ ﻣﺟرى اﻟدم. ﺗؤدي ﻣﺳﺗوﯾﺎت ﺑرادﯾﻛﯾﻧﯾن اﻟزاﺋدة إﻟﻰ اﻹﺻﺎﺑﺔ ﺑﺄﻋراض اﻟوذﻣﺔ</p><p dir="RTL">اﻟوﻋﺎﺋﯾﺔ اﻟوراﺛﯾﺔ (HAE) ﻣﺛل ﺗورم وأﻟم ﻓﻲ،</p><p dir="RTL">&middot; &nbsp;اﻟﯾدﯾن واﻟﻘدﻣﯾن</p><p dir="RTL">&middot; &nbsp;اﻟوﺟﮫ أو اﻟﺟﻔون أو اﻟﺷﻔﺗﯾن أو اﻟﻠﺳﺎن</p><p dir="RTL">&middot; &nbsp;اﻟﺣﻧﺟرة، وﻗد ﯾﺗﺳﺑب ذﻟك ﻓﻲ ﺻﻌوﺑﺔ اﻟﺗﻧﻔس</p><p dir="RTL">&middot; &nbsp;اﻷﻋﺿﺎء اﻟﺗﻧﺎﺳﻠﯾﺔ</p><p><strong>طرﯾﻘﺔ ﻋﻣل ﺗﺎﻛزﯾرو</strong></p><p dir="RTL">ﺗﺎﻛزﯾرو ھو ﻧوع ﻣن أﻧواع اﻟﺑروﺗﯾن ﯾﻌﻣل ﻋﻠﻰ ﻣﻧﻊ ﻧﺷﺎط ﻛﺎﻟﯾﻛرﯾن اﻟﺑﻼزﻣﺎ. وھذا ﯾﺳﺎﻋد ﻋﻠﻰ اﻧﺧﻔﺎض ﻛﻣﯾﺔ ﺑرادﯾﻛﯾﻧﯾن ﻓﻲ ﻣﺟرى</p><p dir="RTL">اﻟدم وﯾﻘﻲ ﻣن أﻋراض اﻟوذﻣﺔ اﻟوﻋﺎﺋﯾﺔ اﻟوراﺛﯾﺔ .(HAE)</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>ﻻ ﺗﺳﺗﺧدم ﺗﺎﻛزﯾرو ﻓﻲ&nbsp;<strong>اﻟﺣﺎﻻت اﻟﺗﺎﻟﯾﺔ:</strong></p><p><strong>&nbsp;</strong></p><p dir="RTL">إذا&nbsp;ﻛﻧت&nbsp;ﻣﺻﺎ&nbsp;ًﺑﺎ&nbsp;ﺑﺎﻟﺣﺳﺎﺳﯾﺔ&nbsp;ﺗﺟﺎه&nbsp;ﻻﻧﺎدﯾﻠوﻣﺎب&nbsp;أو&nbsp;أي&nbsp;ﻣﻛون&nbsp;آﺧر&nbsp;ﻣن&nbsp;ﻣﻛوﻧﺎت&nbsp;ھذا&nbsp;اﻟدواء&nbsp;)اﻟﻣدرﺟﺔ&nbsp;ﻓﻲ&nbsp;اﻟﻘﺳم&nbsp;.(6</p><p><strong>ﺗﺣذﯾرات واﺣﺗﯾﺎطﺎت</strong></p><p dir="RTL">&middot;&nbsp;&nbsp; ﯾُرﺟﻰ&nbsp;اﺳﺗﺷﺎرة&nbsp;اﻟطﺑﯾب&nbsp;أو&nbsp;اﻟﺻﯾدﻟﻲ&nbsp;أو&nbsp;اﻟﻣﻣرﺿﺔ&nbsp;ﻗﺑل&nbsp;اﺳﺗﺧدام&nbsp;ﺗﺎﻛزﯾرو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; إذا&nbsp;أُﺻﺑت&nbsp;ﺑﺗﻔﺎﻋل&nbsp;ﺣﺳﺎﺳﯾﺔ&nbsp;ﺣﺎد&nbsp;ﺗﺟﺎه&nbsp;ﺗﺎﻛزﯾرو&nbsp;ﻣﺻﺣو&nbsp;ًﺑﺎ&nbsp;ﺑﺄﻋراض&nbsp;ﻣﺛل&nbsp;اﻟطﻔﺢ&nbsp;اﻟﺟﻠدي&nbsp;أو&nbsp;ﺿﯾﻖ&nbsp;اﻟﺻدر&nbsp;أو&nbsp;اﻟﺻﻔﯾر&nbsp;ﻋﻧد&nbsp;اﻟﺗﻧﻔس&nbsp;أو</p><p dir="RTL">ﺗﺳﺎرع&nbsp;ﺿرﺑﺎت&nbsp;اﻟﻘﻠب،&nbsp;ﻓﺄﺧﺑر&nbsp;اﻟطﺑﯾب&nbsp;أو&nbsp;اﻟﺻﯾدﻟﻲ&nbsp;أو&nbsp;اﻟﻣﻣرﺿﺔ&nbsp;ﻓو&nbsp;ًرا.</p><p><strong>اﻻﺣﺗﻔﺎظ ﺑﺳﺟل</strong></p><p dir="RTL">ﯾوﺻﻰ ﺑﺷدة ﺑﺗﺳﺟﯾل اﺳم اﻟدواء ورﻗم اﻟدﻓﻌﺔ ﻓﻲ ﻛل ﻣرة ﺗﺗﻠﻘﻰ ﻓﯾﮭﺎ ﺟرﻋﺔ ﻣن ﺗﺎﻛزﯾرو. وذﻟك ﻟﻼﺣﺗﻔﺎظ ﺑﺳﺟل ﻟﻠدﻓﻌﺎت اﻟﻣﺳﺗﺧدﻣﺔ.</p><p><strong>اﻻﺧﺗﺑﺎرات اﻟﻣﻌﻣﻠﯾﺔ</strong></p><p dir="RTL">إذا&nbsp;ﻛﻧت&nbsp;ﺗﺳﺗﺧدم&nbsp;ﺗﺎﻛزﯾرو،&nbsp;ﻓﯾُرﺟﻰ&nbsp;إﺧﺑﺎر&nbsp;اﻟطﺑﯾب&nbsp;ﺑذﻟك&nbsp;ﻗﺑل&nbsp;اﻟﺧﺿوع&nbsp;إﻟﻰ&nbsp;اﻻﺧﺗﺑﺎرات&nbsp;اﻟﻣﻌﻣﻠﯾﺔ&nbsp;ﻟﻘﯾﺎس&nbsp;ﻣدى&nbsp;ﻗدرة&nbsp;اﻟدم&nbsp;ﻋﻠﻰ&nbsp;اﻟﺗﺟﻠط.&nbsp;ذﻟك ﻷن وﺟود ﺗﺎﻛزﯾرو ﻓﻲ اﻟدم ﻗد ﯾؤﺛر ﻋﻠﻰ ﺑﻌض اﻻﺧﺗﺑﺎرات اﻟﻣﻌﻣﻠﯾﺔ، ﻣﺎ ﯾؤدي إﻟﻰ ﻋدم دﻗﺔ ﻧﺗﺎﺋﺟﮭﺎ</p><p><strong>اﻷطﻔﺎل واﻟﻣراھﻘون</strong></p><p dir="RTL">ﻻ ﯾُﻧﺻﺢ ﺑﺎﺳﺗﺧدام ﺗﺎﻛزﯾرو ﻣﻊ اﻷطﻔﺎل اﻟذﯾن ﺗﻘل أﻋﻣﺎرھم ﻋن 12 ﻋﺎ ًﻣﺎ. ذﻟك ﻷﻧﮫ ﻟم ﯾﺗم إﺟراء دراﺳﺎت ﻋﻠﯾﮫ ﻓﻲ ھذه اﻟﻔﺋﺔ اﻟﻌﻣرﯾﺔ.</p><p><strong>اﺳﺗﺧدام اﻷدوﯾﺔ اﻷﺧرى ﻣﻊ ﺗﺎﻛزﯾرو</strong></p><p dir="RTL">ﯾُرﺟﻰ&nbsp;إﺧﺑﺎر&nbsp;اﻟطﺑﯾب&nbsp;أو&nbsp;اﻟﺻﯾدﻟﻲ&nbsp;إذا&nbsp;ﻛﻧت&nbsp;ﺗﺗﻧﺎول&nbsp;أي&nbsp;أدوﯾﺔ&nbsp;أﺧرى&nbsp;أو&nbsp;ﺗﻧﺎوﻟﺗﮭﺎ&nbsp;ﻣؤﺧ&nbsp; ًرا&nbsp;أو&nbsp;ﻗد&nbsp;ﺗﺗﻧﺎوﻟﮭﺎ.</p><p dir="RTL">ﻟﯾس ﻣﻌروﻓًﺎ إذا ﻛﺎن ﺗﺎﻛزﯾرو ﯾؤﺛر ﻋﻠﻰ اﻷدوﯾﺔ اﻷﺧرى أو ﯾﺗﺄﺛر ﺑﮭﺎ.</p><p><strong>اﻟﺣﻣل واﻟرﺿﺎﻋﺔ اﻟطﺑﯾﻌﯾﺔ</strong></p><p dir="RTL">إذا كنت ﺣﺎﻣ ًﻼ أو ﺗرﺿﻌﯾن رﺿﺎﻋﺔ طﺑﯾﻌﯾﺔ أو ﺗﻌﺗﻘدﯾن أﻧﻛ</p><p dir="RTL">ﻗﺑل اﻟﺑدء ﻓﻲ اﺳﺗﺧدام ﺗﺎﻛزﯾرو. ﺗوﺟد ﻣﻌﻠوﻣﺎت ﻣﺣدودة ﻋن ﺳﻼﻣﺔ اﺳﺗﺧدام ﺗﺎﻛزﯾرو أﺛﻧﺎء اﻟﺣﻣل واﻟرﺿﺎﻋﺔ اﻟطﺑﯾﻌﯾﺔ. وﻛﺈﺟراء اﺣﺗرازي،&nbsp;ﯾُﻧﺻﺢ&nbsp;ﺑﺗﺟﻧب&nbsp;اﺳﺗﺧدام&nbsp;ﻻﻧﺎدﯾﻠوﻣﺎب&nbsp;أﺛﻧﺎء&nbsp;اﻟﺣﻣل&nbsp;واﻟرﺿﺎﻋﺔ&nbsp;اﻟطﺑﯾﻌﯾﺔ.&nbsp;ﺳﯾﺗﻧﺎﻗش&nbsp;اﻟطﺑﯾب&nbsp;ﻣﻌك&nbsp;ك ﺑﺧﺻوص ﻣﺧﺎطر ﺗﻧﺎول ھذااﻟدواء وﻓواﺋده.</p><p><strong>اﻟﻘﯾﺎدة واﺳﺗﺧدام اﻵﻻت</strong></p><p dir="RTL">ﻻ&nbsp;ﯾوﺟد&nbsp;ﺗﺄﺛﯾر&nbsp;ﯾُذﻛر&nbsp;ﻟﮭذا&nbsp;اﻟدواء&nbsp;ﻋﻠﻰ&nbsp;اﻟﻘدرة&nbsp;ﻋﻠﻰ&nbsp;اﻟﻘﯾﺎدة&nbsp;أو&nbsp;اﺳﺗﺧدام&nbsp;اﻵﻻت.</p><p><strong>ﯾﺣﺗوي ﺗﺎﻛزﯾرو ﻋﻠﻰ اﻟﺻودﯾوم</strong></p><p dir="RTL">ﯾﺣﺗوي ھذا اﻟدواء ﻋﻠﻰ أﻗل ﻣن 1 ﻣﻠﯾﻣول ﻣن اﻟﺻودﯾوم 23) ﻣﻠﺟم( ﻟﻛل ﻣل ﻣن اﻟﻣﺣﻠول، ﻣﺎ ﯾﻌﻧﻲ أﻧﮫ &quot;ﺧﺎل ﻣن اﻟﺻودﯾوم&quot; ﺗﻘرﯾﺑﺎ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﺗﺎﻛزﯾرو ﻣﺗوﻓر ﻋﻠﻰ ھﯾﺋﺔ ﻣﺣﻠول ﺟﺎھز ﻟﻼﺳﺗﺧدام ﻓﻲ ﻗﻧﯾﻧﺎت ﻣﻌدة ﻟﻼﺳﺗﺧدام ﻟﻣرة واﺣدة. ﺳﯾﺑدأ ﻋﻼﺟك وﺳﺗﺗم إدارﺗﮫ ﺗﺣت إﺷراف طﺑﯾب ﺧﺑﯾر ﻓﻲ رﻋﺎﯾﺔ اﻟﻣرﺿﻰ اﻟﻣﺻﺎﺑﯾن ﺑﺎﻟوذﻣﺔ اﻟوﻋﺎﺋﯾﺔ اﻟوراﺛﯾﺔ .(HAE)</p><p dir="RTL">ﯾُرﺟﻰ اﻟﺣرص دو ًﻣﺎ ﻋﻠﻰ اﺳﺗﺧدام ھذا اﻟدواء ﺗﻣﺎ ًﻣﺎ ﻛﻣﺎ ھو ﻣوﺻوف ﻓﻲ ھذه اﻟﻧﺷرة أو ﻛﻣﺎ أﺧﺑرك اﻟطﺑﯾب أو اﻟﺻﯾدﻟﻲ أو اﻟﻣﻣرﺿﺔ.&nbsp;ﯾُرﺟﻰ&nbsp;اﺳﺗﺷﺎرة&nbsp;اﻟطﺑﯾب&nbsp;أو&nbsp;اﻟﺻﯾدﻟﻲ&nbsp;أو&nbsp;اﻟﻣﻣرﺿﺔ&nbsp;إذا&nbsp;ﻟم&nbsp;ﺗﻛن&nbsp;ﻣﺗﺄﻛدا&nbsp;أو&nbsp;ﻛﺎﻧت&nbsp;ﻟدﯾك&nbsp;أي&nbsp;أﺳﺋﻠﺔ&nbsp;إﺿﺎﻓﯾﺔ&nbsp;ﻋن&nbsp;اﺳﺗﺧدام&nbsp;ھذا اﻟدواء.</p><p><strong>ﻣﻘدار ﺟرﻋﺔ ﺗﺎﻛزﯾرو اﻟواﺟب اﺳﺗﺧداﻣﮭﺎ</strong></p><p dir="RTL">ﺟرﻋﺔ اﻟﺑداﯾﺔ اﻟﻣوﺻﻰ ﺑﮭﺎ ھﻲ 300 ﻣﻠﺟم ﻛل أﺳﺑوﻋﯾن. إذا ﻟم ﺗﺗﻌرض ﻟﻧوﺑﺔ ﻟﻣدة طوﯾﻠﺔ، ﻓﻘد ﯾُﻐ ِّﯾر طﺑﯾﺑك اﻟﺟرﻋﺔ إﻟﻰ 300 ﻣﻠﺟم</p><p dir="RTL">ﻛل 4 أﺳﺎﺑﯾﻊ، ﺧﺎﺻﺔً&nbsp;إذا ﻛﺎن وزن ﺟﺳﻣك ﻣﻧﺧﻔﺿﺎ.</p><p><strong>طرﯾﻘﺔ ﺣﻘن ﺗﺎﻛزﯾرو</strong></p><p dir="RTL">إذا ﻗﻣت ﺑﺣﻘن ﺗﺎﻛزﯾرو ﺑﻧﻔﺳك أو إذا ﻗﺎم ﺑذﻟك ﻣﻘدم اﻟرﻋﺎﯾﺔ، ﻓﯾﺟب أن ﺗﻘرأ أﻧت أو ﻣﻘدم اﻟرﻋﺎﯾﺔ اﻟﺗﻌﻠﯾﻣﺎت اﻟواردة ﻓﻲ ﻗﺳم 7،</p><p dir="RTL">&quot;ﺗﻌﻠﯾﻣﺎت اﻻﺳﺗﺧدام&quot; واﺗﺑﺎﻋﮭﺎ ﺑدﻗﺔ.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp; ﺗﺎﻛزﯾرو&nbsp;ھو&nbsp;دواء&nbsp;ﻟﻠﺣﻘن&nbsp;ﺗﺣت&nbsp;اﻟﺟﻠد&nbsp;&quot;)ﯾُﻌطﻰ&nbsp;ﻋن&nbsp;طرﯾﻖ&nbsp;اﻟﺣﻘن&nbsp;ﺗﺣت&nbsp;اﻟﺟﻠد.(&quot;</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﯾﻣﻛﻧك ﺣﻘن ﻧﻔﺳك أو اﻻﺳﺗﻌﺎﻧﺔ ﺑﻣﻘدم اﻟرﻋﺎﯾﺔ ﻟﻠﻘﯾﺎم ﺑذﻟك.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﯾﺟب أن ﯾوﺿﺢ ﻟك اﻟطﺑﯾب أو اﻟﺻﯾدﻟﻲ أو اﻟﻣﻣرﺿﺔ طرﯾﻘﺔ إﻋداد ﺗﺎﻛزﯾرو وﺣﻘﻧﮫ ﺑﺷﻛل ﺳﻠﯾم ﻗﺑل اﺳﺗﺧداﻣﮫ ﻷول ﻣرة. ﻻ ﺗﻘم</p><p dir="RTL">ﺑﺣﻘن ﻧﻔﺳك أو أي ﺷﺧص آﺧر ﺣﺗﻰ ﺗﺗدرب ﻋﻠﻰ ﺣﻘن اﻟدواء.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;ﻗم ﺑﺈدﺧﺎل اﻹﺑرة ﻓﻲ اﻟﻧﺳﯾﺞ اﻟدھﻧﻲ ﻓﻲ اﻟﺑطن أو اﻟﻔﺧذ أو أﻋﻠﻰ اﻟذراع.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;&nbsp;ﻗم ﺑﺣﻘن اﻟدواء ﻓﻲ ﻣﻛﺎن ﻣﺧﺗﻠف ﻛل ﻣرة.</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;&nbsp;اﺳﺗﺧدم ﻛل ﻗﻧﯾﻧﺔ ﻣن ﺗﺎﻛزﯾرو ﻣرة واﺣدة ﻓﻘط.</p><p><strong>ﻓﻲ ﺣﺎﻟﺔ اﺳﺗﺧدام ﺟرﻋﺔ أﻛﺑر ﻣﻣﺎ ﯾﻧﺑﻐﻲ ﻣن ﺗﺎﻛزﯾرو</strong></p><p dir="RTL">إذا&nbsp;ﺗﻧﺎوﻟت&nbsp;ﺟرﻋﺔ&nbsp;زاﺋدة&nbsp;ﻣن&nbsp;ﺗﺎﻛزﯾرو،&nbsp;ﻓﯾُرﺟﻰ&nbsp;إﺧﺑﺎر&nbsp;اﻟطﺑﯾب&nbsp;ﺑذﻟك&nbsp;أو&nbsp;اﻟﺻﯾدﻟﻲ&nbsp;أو&nbsp;اﻟﻣﻣرﺿﺔ.</p><p><strong>إذا ﻧﺳﯾت ﺗﻧﺎول ﺗﺎﻛزﯾرو</strong></p><p dir="RTL">إذا ﻓﺎﺗﺗك ﺟرﻋﺔ ﻣن ﺗﺎﻛزﯾرو، ﻓﻘم ﺑﺣﻘن ﺟرﻋﺗك ﻓﻲ أﻗرب وﻗت ﻣﻣﻛن ﻣﻊ ﺿرورة ﻣراﻋﺎة أن ﯾﻛون ﺑﯾن ﻛل ﺟرﻋﺔ واﻟﺟرﻋﺔ اﻟﺗﻲ ﺗﻠﯾﮭﺎ&nbsp;ﻓﺗرة&nbsp;ﻻ&nbsp;ﺗﻘل&nbsp;ﻋن&nbsp;10&nbsp;أﯾﺎم.&nbsp;إذا&nbsp;ﻟم&nbsp;ﺗﻛن&nbsp;ﻣﺗﺄﻛ&nbsp;ًدا&nbsp;ﻣن&nbsp;وﻗت&nbsp;ﺣﻘن&nbsp;ﺗﺎﻛزﯾرو&nbsp;ﺑﻌد&nbsp;اﻟﺟرﻋﺔ&nbsp;اﻟﻔﺎﺋﺗﺔ،&nbsp;ﻓﯾُرﺟﻰ&nbsp;ﺳؤال&nbsp;اﻟطﺑﯾب&nbsp;أو&nbsp;اﻟﺻﯾدﻟﻲ&nbsp;أو</p><p dir="RTL">اﻟﻣﻣرﺿﺔ.</p><p><strong>إذا ﺗوﻗﻔت ﻋن ﺗﻧﺎول ﺗﺎﻛزﯾرو</strong></p><p dir="RTL">ﻣن اﻟﻣﮭم اﻻﺳﺗﻣرار ﻓﻲ ﺣﻘن ﺗﺎﻛزﯾرو وﻓﻘًﺎ ﻟﺗﻌﻠﯾﻣﺎت اﻟطﺑﯾب ﺣﺗﻰ ﻟو ﺷﻌرت ﺑﺗﺣﺳن.</p><p dir="RTL">إذا ﻛﺎﻧت ﻟدﯾك أي أﺳﺋﻠﺔ إﺿﺎﻓﯾﺔ ﻋن اﺳﺗﺧدام ھذا اﻟدواء، ﻓﺎﺳﺄل اﻟطﺑﯾب أو اﻟﺻﯾدﻟﻲ أو اﻟﻣﻣرﺿﺔ.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﯾﻣﻛن أن ﯾﺗﺳﺑب ھذا اﻟدواء ﻣﺛل ﺟﻣﯾﻊ اﻷدوﯾﺔ ﻓﻲ ﺣدوث آﺛﺎر ﺟﺎﻧﺑﯾﺔ، ﻋﻠﻰ اﻟرﻏم ﻣن ﻋدم ﺗﻌرض ﺟﻣﯾﻊ اﻟﻣرﺿﻰ ﻟﮭﺎ.</p><p dir="RTL">إذا أُﺻﺑت ﺑﺗﻔﺎﻋل ﺣﺳﺎﺳﯾﺔ ﺣﺎد ﺗﺟﺎه ﺗﺎﻛزﯾرو ﻣﺻﺣوﺑﺎ ﺑﺄﻋراض ﻣﺛل اﻟطﻔﺢ اﻟﺟﻠدي أو ﺿﯾﻖ اﻟﺻدر أو اﻟﺻﻔﯾر ﻋﻧد اﻟﺗﻧﻔس</p><p dir="RTL">أو&nbsp;ﺗﺳﺎرع&nbsp;ﺿرﺑﺎت&nbsp;اﻟﻘﻠب،&nbsp;ﻓﺄﺧﺑر&nbsp;اﻟطﺑﯾب&nbsp;أو&nbsp;اﻟﺻﯾدﻟﻲ&nbsp;أو&nbsp;اﻟﻣﻣرﺿﺔ&nbsp;ﻓو&nbsp; ًرا.</p><p dir="RTL">ﯾُرﺟﻰ&nbsp;إﺧﺑﺎر&nbsp;اﻟطﺑﯾب&nbsp;أو&nbsp;اﻟﺻﯾدﻟﻲ&nbsp;أو&nbsp;اﻟﻣﻣرﺿﺔ&nbsp;إذا&nbsp;ﻻﺣظت&nbsp;أﯾﺎ&nbsp;ﻣن&nbsp;اﻵﺛﺎر&nbsp;اﻟﺟﺎﻧﺑﯾﺔ&nbsp;اﻟﺗﺎﻟﯾﺔ.</p><p><strong>ﺷﺎﺋﻌﺔ ﺟدا )ﻗد ﺗﺻﯾب أﻛﺛر ﻣن ﺷﺧص ﻣن ﻛل 10 أﺷﺧﺎص:(</strong></p><p dir="RTL">&middot; &nbsp;&nbsp;ﺗﻔﺎﻋﻼت ﻣوﺿﻊ اﻟﺣﻘن &ndash; ﺗﺷﻣل اﻷﻋراض اﻷﻟم واﺣﻣرار اﻟﺟﻠد واﻟﻛدﻣﺎت واﻟﺷﻌور ﺑﻌدم اﻟراﺣﺔ واﻟﺗورم واﻟﻧزﯾف واﻟﺣﻛﺔ اﻟﺟﻠدﯾﺔ وﺗﯾﺑس اﻟﺟﻠد واﻟوﺧز واﻟدفء واﻟطﻔﺢ.</p><p><strong>ﺷﺎﺋﻌﺔ )ﻗد ﺗﺻﯾب ﻣﺎ ﯾﺻل إﻟﻰ ﺷﺧص ﻣن ﻛل 10 أﺷﺧﺎص:(</strong></p><p dir="RTL">&middot; &nbsp;&nbsp;ﺗﺷﻣل ﺗﻔﺎﻋﻼت اﻟﺣﺳﺎﺳﯾﺔ اﻟﺣﻛﺔ اﻟﺟﻠدﯾﺔ واﻟﺷﻌور ﺑﻌدم اﻟراﺣﺔ ووﺧز اﻟﻠﺳﺎن</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻟدوار واﻟﺷﻌور ﺑﺎﻹﻏﻣﺎء</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;اﻟطﻔﺢ اﻟﺟﻠدي اﻟﺑﺎرز</p><p dir="RTL">&middot; &nbsp;&nbsp;&nbsp;أﻟم ﻓﻲ اﻟﻌﺿﻼت</p><p dir="RTL">&middot; &nbsp;&nbsp;اﺧﺗﺑﺎرات اﻟدم اﻟﺗﻲ ﺗوﺿﺢ ﺗﻐﯾﯾرات ﻓﻲ اﻟﻛﺑد</p><p><strong>اﻹﺑﻼغ ﻋن اﻵﺛﺎر اﻟﺟﺎﻧﺑﯾﺔ</strong></p><p dir="RTL">&middot;<strong> </strong><strong>اﻟﻣﻣﻠﻛﺔ </strong><strong>اﻟﻌرﺑﯾﺔ </strong><strong>اﻟﺳﻌودﯾﺔ</strong><strong>:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">- اﻟﻣرﻛز اﻟوطﻧﻲ ﻟﻠﺗﯾﻘظ واﻟﺳﻼﻣﺔ اﻟدواﺋﯾﺔ</p><p>+966-11-205-7662 :ﻓﺎﻛس</p><p dir="RTL">اﺗﺻل ﺑﺎﻟﻣرﻛز اﻟوطﻧﻲ ﻟﻠﺗﯾﻘظ واﻟﺳﻼﻣﺔ اﻟدواﺋﯾﺔ ﻋﻠﻰ رﻗم +966-11-2038222، اﻟرﻗم اﻟداﺧﻠﻲ: -2356-2353-2317</p><p>اﻟﮭﺎﺗف اﻟﻣﺟﺎﻧﻲ: 8002490000</p><p dir="RTL">اﻟﺑرﯾد اﻹﻟﻛﺗروﻧﻲ: npc.drug@sfda.gov.sa</p><p dir="RTL">اﻟﻣوﻗﻊ اﻹﻟﻛﺗروﻧﻲ:&nbsp;&nbsp; www.sfda.gov.sa/npc</p></td></tr></tbody></table><p dir="RTL">&middot;<strong> &nbsp;</strong><strong>دول </strong><strong>ﻣﺟﻠس </strong><strong>اﻟﺗﻌﺎون </strong><strong>اﻟﺧﻠﯾﺟﻲ </strong><strong>اﻷﺧرى</strong><strong>:</strong></p><table border="1" cellspacing="1" cellpadding="1" style="width:500px"><tbody><tr><td><p dir="RTL">- ﯾرﺟﻰ اﻻﺗﺻﺎل ﺑﺎﻟﺳﻠطﺔ اﻟﻣﺧﺗﺻﺔ ذات اﻟﺻﻠﺔ.</p></td></tr></tbody></table><p><!--[if gte vml 1]><o:wrapblock><v:shapetype
  id="_x0000_t202" coordsize="21600,21600" o:spt="202" path="m,l,21600r21600,l21600,xe">
  <v:stroke joinstyle="miter"/>
  <v:path gradientshapeok="t" o:connecttype="rect"/>
 </v:shapetype><v:shape id="_x0000_s1026" type="#_x0000_t202" style='position:absolute;
  margin-left:48.55pt;margin-top:18.65pt;width:474.55pt;height:21.25pt;
  z-index:-251652096;mso-wrap-distance-left:0;mso-wrap-distance-right:0;
  mso-position-horizontal-relative:page' filled="f" strokeweight=".25pt">
  <v:textbox inset="0,0,0,0">
   <![if !mso]>
   <table cellpadding=0 cellspacing=0 width="100%">
    <tr>
     <td><![endif]>
     <div>
     <p class=MsoBodyText align=right dir=RTL style='margin-top:3.55pt;
     margin-right:0in;margin-bottom:0in;margin-left:3.9in;margin-bottom:.0001pt;
     text-align:left;direction:rtl;unicode-bidi:embed'><span dir=LTR>-</span><span
     dir=RTL></span><span dir=RTL></span><span style='letter-spacing:2.9pt'><span
     dir=RTL></span><span dir=RTL></span> </span><span lang=AR-SA
     style='mso-bidi-language:AR-SA'>ﯾرﺟﻰ</span><span lang=AR-SA> </span><span
     lang=AR-SA style='mso-bidi-language:AR-SA'>اﻻﺗﺻﺎل</span><span lang=AR-SA> </span><span
     lang=AR-SA style='mso-bidi-language:AR-SA'>ﺑﺎﻟﺳﻠطﺔ</span><span lang=AR-SA>
     </span><span lang=AR-SA style='mso-bidi-language:AR-SA'>اﻟﻣﺧﺗﺻﺔ</span><span
     lang=AR-SA> </span><span lang=AR-SA style='mso-bidi-language:AR-SA'>ذات</span><span
     lang=AR-SA> </span><span lang=AR-SA style='mso-bidi-language:AR-SA'>اﻟﺻﻠﺔ</span><span
     dir=LTR></span><span dir=LTR></span><span dir=LTR><span dir=LTR></span><span
     dir=LTR></span>.<o:p></o:p></span></p>
     </div>
     <![if !mso]></td>
    </tr>
   </table>
   <![endif]></v:textbox>
  <w:wrap type="topAndBottom" anchorx="page"/>
 </v:shape><![endif]--></p><table cellpadding="0" cellspacing="0" align="left"><tbody><tr><td>&nbsp;</td></tr><tr><td>&nbsp;</td><td>&nbsp;</td></tr></tbody></table><p><!--[if gte vml 1]></o:wrapblock><![endif]--></p><p>&nbsp;</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﯾُﺣﻔظ&nbsp;ھذا&nbsp;اﻟدواء&nbsp;ﺑﻌﯾدا&nbsp;ﻋن&nbsp;ﻣرأى&nbsp;اﻷطﻔﺎل&nbsp;وﻣﺗﻧﺎوﻟﮭم.</p><p dir="RTL">ﻻ ﺗﺳﺗﺧدم ھذا اﻟدواء ﺑﻌد ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ اﻟﻣذﻛور ﻋﻠﻰ اﻟﻣﻠﺻﻖ ﺑﻌد ﻛﻠﻣﺔ .EXP ﯾﺷﯾر ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ إﻟﻰ آﺧر ﯾوم ﻣن اﻟﺷﮭر اﻟﻣذﻛور.</p><p dir="RTL">ﯾُﺣﻔظ&nbsp;ﻓﻲ&nbsp;اﻟﺛﻼﺟﺔ&nbsp;ﻓﻲ&nbsp;درﺟﺔ&nbsp;ﺣرارة&nbsp;2�-8�)&nbsp;درﺟﺎت&nbsp;ﻣﺋوﯾﺔ.(&nbsp;ﻻ&nbsp;ﺗﻘم&nbsp;ﺑﺗﺟﻣﯾد&nbsp;اﻟﻣﻧﺗﺞ.&nbsp;اﺣﻔظ&nbsp;اﻟﻘﻧﯾﻧﺔ&nbsp;ﻓﻲ&nbsp;اﻟﻌﻠﺑﺔ&nbsp;اﻟﻛرﺗوﻧﯾﺔ&nbsp;اﻟﺧﺎرﺟﯾﺔ ﻟﺣﻣﺎﯾﺗﮭﺎ ﻣن اﻟﺿوء.</p><p dir="RTL">ﯾﻣﻛن ﺗﺧزﯾن اﻟﻘﻧﯾﻧﺎت ﺗﺣت درﺟﺔ ﺣرارة 25 درﺟﺔ ﻣﺋوﯾﺔ ﻟﻔﺗرة واﺣدة ﻣدﺗﮭﺎ 14 ﯾو&nbsp; ًﻣﺎ، ﻓﯾﻣﺎ ﻻ ﯾﺗﻌدى ﺗﺎرﯾﺦ اﻧﺗﮭﺎء اﻟﺻﻼﺣﯾﺔ. ﻻ ﺗﻘم ﺑﺈﻋﺎدة ﺗﺧزﯾن ﺗﺎﻛزﯾرو داﺧل اﻟﺛﻼﺟﺔ ﺑﻌد ﺗﺧزﯾﻧﮫ ﻓﻲ درﺟﺔ ﺣرارة اﻟﻐرﻓﺔ.</p><p dir="RTL">ﻻ ﺗﺳﺗﺧدم ھذا اﻟدواء إذا ﻻﺣظت ﻋﻼﻣﺎت ﺗدل ﻋﻠﻰ ﺗﻠﻔﮫ ﻣﺛل ﻣﻼﺣظﺔ ﺟﺳﯾﻣﺎت ﻓﻲ اﻟﻘﻧﯾﻧﺔ أو ﺗﻐﯾر ﻓﻲ ﻟون ﻣﺣﻠول اﻟﺣﻘن.</p><p dir="RTL">ﻻ ﺗﺗﺧﻠص ﻣن أي أدوﯾﺔ ﻋﺑر ﻣﯾﺎه اﻟﺻرف اﻟﺻﺣﻲ أو اﻟﻣﺧﻠﻔﺎت اﻟﻣﻧزﻟﯾﺔ. اﺳﺄل اﻟﺻﯾدﻟﻲ اﻟذي ﺗﺗﻌﺎﻣل ﻣﻌﮫ ﻋن ﻛﯾﻔﯾﺔ اﻟﺗﺧﻠص ﻣن اﻷدوﯾﺔ اﻟﺗﻲ ﻟم ﺗﻌد ﺗﺳﺗﺧدﻣﮭﺎ. ﺳﺗﺳﺎﻋد ھذه اﻟﺗداﺑﯾر ﻋﻠﻰ ﺣﻣﺎﯾﺔ اﻟﺑﯾﺋﺔ</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">&middot;&nbsp;&nbsp;اﻟﻣﺎدة&nbsp;اﻟﻔ&nbsp; ّﻌﺎﻟﺔ&nbsp;ھﻲ&nbsp;ﻻﻧﺎدﯾﻠوﻣﺎب.&nbsp;ﺗﺣﺗوي&nbsp;ﻛل&nbsp;ﻗﻧﯾﻧﺔ&nbsp;ﻋﻠﻰ&nbsp;300&nbsp;ﻣﻠﺟم&nbsp;ﻣن&nbsp;ﻻﻧﺎدﯾﻠوﻣﺎب&nbsp;2&nbsp;ﻣل.</p><p dir="RTL">&middot; &nbsp;اﻟﻣﻛوﻧﺎت اﻷﺧرى ھﻲ ﺛﻧﺎﺋﻲ ھﯾدرات ﻓوﺳﻔﺎت ﺛﻧﺎﺋﻲ اﻟﺻودﯾوم و أﺣﺎدي ھﯾدرات ﺣﻣض اﻟﺳﺗرﯾك وھﯾﺳﺗدﯾن وﻛﻠورﯾد اﻟﺻودﯾوم وﺑوﻟﯾﺳورﺑﯾت 80 وﻣﺎء ﻟﻠﺣﻘن &ndash; اﻧظر اﻟﻘﺳم 2 &quot;ﯾﺣﺗوي ﺗﺎﻛزﯾرو ﻋﻠﻰ اﻟﺻودﯾوم&quot;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ﯾﺗوﻓر ﺗﺎﻛزﯾرو ﻓﻲ ﺷﻛل ﻣﺣﻠول ﻟﻠﺣﻘن ﺻﺎلح للاستخدام&nbsp;ﻋدﯾم اﻟﻠون أو أﺻﻔر ﻗﻠﯾ ًﻼ ﻣﻌﺑﺄ ﻓﻲ ﻗﻧﯾﻧﺔ زﺟﺎﺟﯾﺔ.</p><p dir="RTL">ﺗﺎﻛزﯾرو ﻣﺗوﻓر ﻛﻌﺑوة واﺣدة ﺗﺣﺗوي&nbsp;ﻋﻠﻰ ﻗﻧﯾﻧﺔ ﺳﻌﺔ 2 ﻣل.</p><p dir="RTL">ﻛﻣﺎ ﺗﺣﺗوي ﻛل ﻋﺑوة ﻋﻠﻰ اﻟﻌﻧﺎﺻر اﻟﺗﺎﻟﯾﺔ:</p><p dir="RTL">&middot; &nbsp;ﻣﺣﻘﻧﺔ ﻓﺎرﻏﺔ ﺳﻌﺔ 3 ﻣل</p><p dir="RTL">&middot; &nbsp;إﺑرة ﺑﺳن ﻛﻠﯾل ﻋﯾﺎر 18 ﻟﺳﺣب اﻟدواء ﻣن اﻟﻘﻧﯾﻧﺔ.</p><p dir="RTL">&middot; &nbsp;إﺑرة ﺣﻘن ﺑﺳن ﻣدﺑب ﻋﯾﺎر 27، ﻣﻘﺎس &frac12; ﺑوﺻﺔ 0.4)&nbsp;.(ﻣﻠم13x</p><p>&nbsp;</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>ﺣﺎﻣل ﺗرﺧﯾص اﻟﺗﺳوﯾﻖ:</strong></p><p>Shire Pharmaceuticals Ireland Limited Blocks 2 &amp; 3 Miesian Plaza Baggot Street Lower 58-50</p><p>Dublin 2</p><p dir="RTL">أﯾرﻟﻧدا</p><p>959 894 1256(0)44+ :اﻟﮭﺎﺗف</p><p dir="RTL">اﻟﺑرﯾد اﻹﻟﻛﺗروﻧﻲ: medinfoEMEA@shire.com</p><p dir="RTL"><strong>اﻟﺷرﻛﺔ اﻟﻣﺻﻧﻌﺔ:</strong></p><p>Catalent Indiana, LLC - USA</p><p>ﻟﻠﻣزﯾد ﻣن اﻟﻣﻌﻠوﻣﺎت ﺑﺧﺻوص ھذا اﻟداء ﯾرﺟﻰ اﻟﺗواﺻل ﻣﻊ اﻟﻣﻛﺗب اﻟﻌﻠﻣﻲ ﻟﻠﺷرﻛﺔ:</p><p dir="RTL">ﺷﺎﯾر إﻛﺳﺑورت ﺳﯾرﻓﯾﺳﯾز ﺟﻰ ام ﺑﻰ إﺗش 2908 طرﯾﻖ اﻟﻌﻠﯾﺎ ﺣﻲ اﻟﺻﺣﺎﻓﺔ</p><p dir="RTL">ﺳﻧﺗرﯾﺎ ﻣول اﻟدور اﻟﺧﺎﻣس، ﻣﻛﺗب 502</p><p dir="RTL">اﻟرﯾﺎض -12241&nbsp; اﻟﻣﻣﻠﻛﺔ اﻟﻌرﺑﯾﺔ اﻟﺳﻌودﯾﺔ</p><p>0114854959 :ﺗﻠﻔون</p><p dir="RTL">&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            ﺗﻣت اﻟﻣراﺟﻌﺔ اﻷﺧﯾرة ﻟﮭذه اﻟﻧﺷرة ﻓﻲ .2019/02

ھذا اﻟﻣﻧﺗﺞ دواء
-    اﻟدواء ھو ﻣﻧﺗﺞ ﯾؤﺛر ﻋﻠﻰ ﺻﺣﺗك وﯾُﻌرﺿك اﺳﺗﺧداﻣﮫ ﻋﻠﻰ ﻧﺣو ﻣﺧﺎﻟف ﻟﻠﺗﻌﻠﯾﻣﺎت ﻟﻠﺧطر.
-     اﺗﺑﻊ ﺑدﻗﺔ وﺻﻔﺔ اﻟطﺑﯾب، إﻟﻰ ﺟﺎﻧب طرﯾﻘﺔ اﻻﺳﺗﺧدام وﺗﻌﻠﯾﻣﺎت اﻟﺻﯾدﻻﻧﻲ اﻟذي ﺑﺎع ﻟك اﻟدواء.
-     اﻟطﺑﯾب واﻟﺻﯾدﻻﻧﻲ ھﻣﺎ أھل اﻟﺧﺑرة ﺑﺎﻷدوﯾﺔ وﻣﺎ ﻟﮭﺎ ﻣن ﻓواﺋد وﻣﺧﺎطر.
-     ﻻ ﺗﻘطﻊ ﻓﺗرة اﻟﻌﻼج اﻟﻣوﺻوف ﻣن ﻧﻔﺳك.
-     ﻻ ﺗﻛرر ﺻرف اﻟوﺻﻔﺔ اﻟطﺑﯾﺔ دون اﺳﺗﺷﺎرة اﻟطﺑﯾب.
- اﺣﻔظ ﺟﻣﯾﻊ اﻷدوﯾﺔ ﺑﻌﯾ  ًدا ﻋن ﻣﺗﻧﺎول اﻷطﻔﺎل.
ﻣﺟﻠس وزراء اﻟﺻﺣﺔ اﻟﻌرب
اﺗﺣﺎد اﻟﺻﯾﺎدﻟﺔ اﻟﻌرب

        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                TAKHZYRO 300 mg solution for injection
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                One vial contains 300 mg of lanadelumab* in 2 mL solution.

*Lanadelumab is produced in Chinese Hamster Ovary (CHO) cells by recombinant DNA technology. 
For the full list of excipients, see section 6.1.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Solution for injection.

The solution is colourless to slightly yellow, appearing either clear or slightly opalescent.

The solution has a pH of approximately 6.0 and an osmolality of approximately 300 mOsm/kg.

            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TAKHZYRO is indicated for routine prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>This medicinal product should be initiated under the supervision of a physician experienced in the management of patients with hereditary angioedema (HAE).</p><p><u>Posology</u></p><p>The recommended starting dose is 300 mg lanadelumab every 2 weeks. In patients who are stably attack free on treatment, a dose reduction of 300 mg lanadelumab every 4 weeks may be considered, especially in patients with low weight.</p><p>TAKHZYRO is not intended for treatment of acute HAE attacks (see section 4.4)</p><p><em>Missed doses</em></p><p>If a dose of TAKHZYRO is missed, the patient should be instructed to administer the dose as soon as possible ensuring at least 10 days between doses.</p><p><u>Special populations</u></p><p><em>Elderly</em></p><p>Age is not expected to affect exposure to lanadelumab. No dose adjustment is required for patients above 65 years of age (see section 5.2).</p><p><em>Hepatic impairment</em></p><p>No studies have been conducted in patients with hepatic impairment. Hepatic impairment is not expected to affect exposure to lanadelumab. No dose adjustment is required in patients with hepatic impairment (see section 5.2).</p><p><em>Renal impairment</em></p><p>No studies have been conducted in patients with severe renal impairment. Renal impairment is not expected to affect exposure to lanadelumab or the safety profile. No dose adjustment is required in patients with renal impairment. (see section 5.2).</p><p><em>Paediatric population</em></p><p>The safety and efficacy of TAKHZYRO in children aged less than 12 years have not been established. No data are available.</p><p><u>Method of administration</u></p><p>TAKHZYRO is intended for subcutaneous (SC) administration only. Each TAKHZYRO vial is intended for single use only (see section 6.6).</p><p>The injection should be restricted to the recommended injection sites: the abdomen, the thighs, and the upper outer arms (see section 5.2). Rotation of the injection site is recommended.</p><p>TAKHZYRO may be self-administered or administered by a caregiver only after training on SC injection technique by a healthcare professional.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Traceability</u></p><p>In order to improve the traceability of biological medicinal products, the name and the batch number of the administered product should be clearly recorded.</p><p><u>Hypersensitivity reactions</u></p><p>Hypersensitivity reactions have been observed. In case of a severe hypersensitivity reaction, administration of TAKHZYRO must be stopped immediately and appropriate treatment must be initiated.</p><p><u>General</u></p><p>TAKHZYRO is not intended for treatment of acute HAE attacks. In case of a breakthrough HAE attack, individualized treatment should be initiated with an approved rescue medication.</p><p>There are no available clinical data on the use of lanadelumab in HAE patients with normal C1-INH activity.</p><p><u>Interference with coagulation test</u></p><p>Lanadelumab can increase activated partial thromboplastin time (aPTT) due to an interaction of lanadelumab with the aPTT assay. The reagents used in the aPTT laboratory test initiate intrinsic coagulation through the activation of plasma kallikrein in the contact system. Inhibition of plasma kallikrein by lanadelumab can increase aPTT in this assay. None of the increases in aPTT in patients treated with TAKHZYRO were associated with abnormal bleeding adverse events. There were no differences in international normalised ratio (INR) between treatment groups.</p><p><u>Sodium content</u></p><p>This medicinal product contains less than 1 mmol sodium (23 mg) per vial, that is to say essentially &#39;sodium-free&#39;.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No dedicated drug-drug interaction studies have been conducted. Based on the characteristics of lanadelumab, no pharmacokinetic interactions with co-administered medicinal products is expected.</p><p>As expected, concomitant use of the rescue medication C1 esterase inhibitor results in an additive effect on lanadelumab-cHMWK response based on the mechanism of action (MOA) of lanadelumab and C1 esterase inhibitor (see section 5.1).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Pregnancy</u></p><p>There are no or limited data from the use of lanadelumab in pregnant women. Animal studies do not indicate direct or indirect harmful effects with respect to reproductive or developmental toxicity (see section 5.3). As a precautionary measure, it is preferable to avoid the use of lanadelumab during pregnancy.</p><p><u>Breast-feeding</u></p><p>It is unknown whether lanadelumab is excreted in human milk. Human IgGs are known to be excreted in breast milk during the first few days after birth, which is decreasing to low concentrations soon afterwards; consequently, a risk to the breast-fed child cannot be excluded during this short period.</p><p>Afterwards, lanadelumab could be used during breast-feeding if clinically needed.</p><p><u>Fertility</u></p><p>Lanadelumab&rsquo;s effect on fertility has not been evaluated in humans. Lanadelumab had no effect on male or female fertility in cynomolgus monkeys (see section 5.3).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>TAKHZYRO has negligible influence on the ability to drive or use machines.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Summary of the safety profile</u></p><p>The most commonly (52.4%) observed adverse reaction associated with TAKHZYRO was injection site reactions (ISR) including injection site pain, injection site erythema and injection site bruising. Of these ISRs, 97% were of mild intensity, 90% resolved within 1 day after onset with a median duration of 6 minutes.</p><p>Hypersensitivity reaction (mild and moderate pruritus, discomfort and tingling of tongue) was observed (1.2%), see section 4.4.</p><p><u>Tabulated list of adverse reactions</u></p><p>Table 1 summarises adverse reactions observed in the HELP study that included 84 subjects with HAE, who received at least one dose of TAKHZYRO.</p><p>The frequency of adverse reactions listed in Table 1 is defined using the following convention:</p><p>Very&nbsp; common&nbsp; (&ge; 1/10);&nbsp; common&nbsp; (&ge; 1/100&nbsp; to&nbsp; &lt; 1/10);&nbsp; uncommon&nbsp; (&ge; 1/1,000&nbsp; to&nbsp; &lt; 1/100);&nbsp; rare&nbsp; (&ge; 1/10,000 to &lt; 1/1,000); very rare (&lt; 1/10,000).</p><p><strong>Table 1: Adverse reactions reported with lanadelumab</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>System organ class</strong></p></td><td style="vertical-align:top"><p><strong>Adverse drug reaction</strong></p></td><td style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Hypersensitivity*</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Dizziness</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Rash maculo-papular</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Myalgia</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Injection site reactions**</p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Very common</p></td></tr><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p>Investigations</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Common</p></td></tr></tbody></table><p><sub>*Hypersensitivity includes: pruritus, discomfort and tingling of tongue.</sub></p><p><sub>**Injection site reactions include: pain, erythema, bruising, discomfort, haematoma, haemorrhage, pruritus, swelling, induration, paraesthesia, reaction, warmth, oedema and rash</sub></p><p>&nbsp;</p><p><u>Paediatric population</u></p><p>The safety of TAKHZYRO was evaluated in a subgroup of 23 subjects aged 12 to &lt;18 years old. Results of the subgroup analysis were consistent with overall study results for all subjects.</p><p><u>Immunogenicity</u></p><p>Treatment with lanadelumab has been associated with development of treatment emergent anti-drug antibodies (ADA) in 11.9% (10/84) of subjects. All antibody titres were low. The ADA response was transient in 20% (2/10) of ADA positive subjects. 2.4% (2/84) of lanadelumab-treated subjects tested positive for neutralizing antibodies.</p><p>The development of ADA including neutralising antibodies against TAKHZYRO did not appear to adversely affect the pharmacokinetic (PK) and pharmacodynamics (PD) profiles or clinical response.</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <em>To reports any side effect(s):</em></p><p><strong><em>Saudi Arabia:</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The National Pharmacovigilance and Drug Safety Centre (NPC)</p><p>o Fax: +966-11-205-7662</p><p>o Call NPC at +966-11-2038222, Exts: 2317-2356-2353-2354-2334-2340.</p><p>o&nbsp;&nbsp;&nbsp; Toll free phone: 8002490000</p><p>o&nbsp;&nbsp;&nbsp; E-mail: npc.drug@sfda.gov.sa</p><p>o&nbsp;&nbsp;&nbsp; Website: www.sfda.gov.sa/npc</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong><em>Other GCC States:</em></strong></p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No case of overdose has been reported. There is no available information to identify potential signs and symptoms of overdose. If symptoms should occur, symptomatic treatment is recommended. There is no antidote available.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Other haematological agents, drugs used in hereditary angioedema, ATC code: B06AC05</p><p><u>Mechanism of action</u></p><p>Lanadelumab is a fully human, monoclonal antibody (IgG1/ &kappa;-light chain). Lanadelumab inhibits active plasma kallikrein proteolytic activity. Increased plasma kallikrein activity leads to angioedema attacks in patients with HAE through the proteolysis of high-molecular-weight-kininogen (HMWK) to generate cleaved HMWK (cHMWK) and bradykinin. Lanadelumab provides sustained control of plasma kallikrein activity and thereby limits bradykinin generation in patients with HAE.</p><p><u>Pharmacodynamic effects</u></p><p>Concentration-dependent inhibition of plasma kallikrein, measured as reduction of cHMWK levels, was demonstrated after SC administration of TAKHZYRO 150 mg every 4 weeks, 300 mg every</p><p>4 weeks or 300 mg every 2 weeks in subjects with HAE.</p><p>The PK-PD relationship between TAKHZYRO and cHMWK is described by an indirect exposure- response pharmacological model. The cHMWK formation rate was maximally reduced by 53.7% with an IC50 of 5705 ng/ml.</p><p><u>Clinical efficacy and safety</u></p><p><em>HELP study</em></p><p>The HELP study was a multicenter, randomised, double-blind, placebo-controlled parallel-group study in 125 (115 adults and 10 adolescents) subjects with symptomatic type I or II HAE. Subjects were randomized into 1 of 4 parallel treatment arms, stratified by baseline attack rate, in a 3:2:2:2 ratio (placebo, lanadelumab 150 mg every 4 weeks [q4wks], lanadelumab 300 mg every 4 weeks [q4wks], or lanadelumab 300 mg every 2 weeks [q2wks] by SC injection) for the 26-week treatment period.</p><p>The median (range) age of the study population was 42 (12 to 73) years with 88 female subjects (70%). A history of laryngeal angioedema attacks was reported in 65% (81/125) of subjects and 56% (70/125) were on prior long term prophylaxis (LTP). During the study run-in period, the mean attack rate was 3.7 attacks/month with 52% (65/125) of subjects experiencing &ge;3 attacks/month.</p><p>All TAKHZYRO treatment arms produced statistically significant reductions in the mean HAE attack rate compared to placebo across all primary and secondary endpoints in the Intent-to-Treat population (ITT) (Table 2).</p><p><strong>Table 2. Results of primary and secondary efficacy measures-ITT population</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>&nbsp;</strong></p><p><strong>Endpoint statistics</strong><strong>a</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Placebo (N=41)</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Lanadelumab</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>150mg q4wks (N=28)</strong></p></td><td style="vertical-align:top"><p><strong>300 mg q4wks (N=29)</strong></p></td><td style="vertical-align:top"><p><strong>300 mg q2wks (N=27)</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Primary endpoint - Number of HAE attacks from Day 0 to 182</strong></p></td></tr><tr><td style="vertical-align:top"><p>LS Mean (95% CI) monthly attack rate<strong>b</strong></p></td><td style="vertical-align:top"><p>1.97 (1.64,</p><p>2.36)</p></td><td style="vertical-align:top"><p>0.48 (0.31,</p><p>0.73)</p></td><td style="vertical-align:top"><p>0.53 (0.36,</p><p>0.77)</p></td><td style="vertical-align:top"><p>0.26 (0.14,</p><p>0.46)</p></td></tr><tr><td style="vertical-align:top"><p>% Reduction relative to placebo (95% CI)<strong>c</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>76 (61, 85)</p></td><td style="vertical-align:top"><p>73 (59, 82)</p></td><td style="vertical-align:top"><p>87 (76, 93)</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted p-values<strong>d</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Secondary endpoint - Number of HAE attacks requiring acute treatment from Day 0 to 182</strong></p></td></tr><tr><td style="vertical-align:top"><p>LS Mean (95% CI) monthly attack rate<strong>b</strong></p></td><td style="vertical-align:top"><p>1.64 (1.34,</p><p>2.00)</p></td><td style="vertical-align:top"><p>0.31 (0.18,</p><p>0.53)</p></td><td style="vertical-align:top"><p>0.42 (0.28,</p><p>0.65)</p></td><td style="vertical-align:top"><p>0.21 (0.11,</p><p>0.40)</p></td></tr><tr><td style="vertical-align:top"><p>% Reduction relative to placebo (95% CI)<strong>c</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>81 (66, 89)</p></td><td style="vertical-align:top"><p>74 (59, 84)</p></td><td style="vertical-align:top"><p>87 (75, 93)</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted p-values<strong>d</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Secondary endpoint - Number of moderate or severe HAE attacks from Day 0 to 182</strong></p></td></tr><tr><td style="vertical-align:top"><p>LS Mean (95% CI) monthly attack rate<strong>b</strong></p></td><td style="vertical-align:top"><p>1.22 (0.97,</p><p>1.52)</p></td><td style="vertical-align:top"><p>0.36 (0.22,</p><p>0.58)</p></td><td style="vertical-align:top"><p>0.32 (0.20,</p><p>0.53)</p></td><td style="vertical-align:top"><p>0.20 (0.11,</p><p>0.39)</p></td></tr><tr><td style="vertical-align:top"><p>% Reduction relative to placebo (95% CI)<strong>c</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>70 (50, 83)</p></td><td style="vertical-align:top"><p>73 (54, 84)</p></td><td style="vertical-align:top"><p>83 (67, 92)</p></td></tr><tr><td style="vertical-align:top"><p>Adjusted p-values<strong>d</strong></p></td><td style="vertical-align:top"><p>&nbsp;</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td><td style="vertical-align:top"><p>&lt;0.001</p></td></tr></tbody></table><p><sub>Note: CI=confidence interval; LS=least squares.</sub></p><p><sub><strong>a </strong>Results are from a Poisson regression model accounting for over dispersion with fixed effects for treatment group (categorical) and normalized baseline attack rate (continuous), and the logarithm of time in days each subject was observed during the treatment period as an offset variable in the model. <strong>b </strong>Model-based treatment period HAE attack rate (attacks/4 weeks).</sub></p><p><sub><strong>c </strong>% reduction relative to placebo corresponds to 100% * (1-rate ratio). The rate ratio is ratio of the model-based treatment period HAE attack rates.</sub></p><p><sub><strong>d </strong>Adjusted p-values for multiple testing.</sub></p><p>&nbsp;</p><p>The mean reduction in HAE attack rate was consistently higher across the TAKHZYRO treatment arms compared to placebo regardless of the baseline history of LTP, laryngeal attacks, or attack rate during the run-in period. The percentage of subjects who were attack free is provided in Table 3.</p><p><strong>Table 3. Percentage of subjects who were attack free through treatment</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Criteria</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Placebo</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Lanadelumab</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>150 mg q4wks</strong></p></td><td style="vertical-align:top"><p><strong>300 mg q4wks</strong></p></td><td style="vertical-align:top"><p><strong>300 mg q2wks</strong></p></td></tr><tr><td colspan="5" style="vertical-align:top"><p><strong>Treatment period (Day 0 to Day 182, 26 weeks)</strong></p></td></tr><tr><td style="vertical-align:top"><p>n</p></td><td style="vertical-align:top"><p>41</p></td><td style="vertical-align:top"><p>28</p></td><td style="vertical-align:top"><p>29</p></td><td style="vertical-align:top"><p>27</p></td></tr><tr><td style="vertical-align:top"><p>Attack free</p></td><td style="vertical-align:top"><p>2%</p></td><td style="vertical-align:top"><p>39%</p></td><td style="vertical-align:top"><p>31%</p></td><td style="vertical-align:top"><p>44%</p></td></tr></tbody></table><p>&nbsp;</p><p>The percentage of patients who were attack free for the last 16-weeks (Day 70 to Day 182) of the study was 77% in the 300 mg q2wks group, compared to 3% of patients in the placebo group.</p><p>100% of the subjects on 300 mg q2wks or q4wks and 89% on 150 mg q4wks achieved at least a 50% reduction in HAE attack rate compared to the run-in period.</p><p><em>Health related Quality of Life</em></p><p>All TAKHZYRO treatment groups observed an improvement in Angioedema Quality of Life Questionnaire (AE-QoL) total and domain (functioning, fatigue/mood, fear/shame, and nutrition) scores compared to the placebo group; the largest improvement was observed in the functioning score as shown in Table 4. A reduction of 6 points is considered a clinically meaningful improvement. The percentage of patients who achieved a clinically meaningful improvement in AE-QoL total score was 65% (Odds ratio vs placebo, [95% CI]= 3.2 [1.1, 9.2]), 63% (2.9 [1.1, 8.1]), and 81% (7.2 [2.2, 23.4]),</p><p>in TAKHZYRO 150 mg q4 wks, 300 mg q4 wks, and 300 mg q2 wks groups, respectively, compared to 37% of patients in the placebo group.</p><p><strong>Table 4 Change in AE-QoL scorea - placebo vs TAKHZYRO at week 26 in HELP study</strong></p><table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>LS mean change (SD) from baseline at week 26</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Placebo</strong></p></td><td style="vertical-align:top"><p><strong>TAKHZYRO</strong></p><p><strong>total</strong></p></td></tr><tr><td style="vertical-align:top"><p>AE-QoL Total score</p></td><td style="vertical-align:top"><p>-4.7 (18.8)</p></td><td style="vertical-align:top"><p>-19.5 (18.6)</p></td></tr><tr><td style="vertical-align:top"><p>Functioning score</p></td><td style="vertical-align:top"><p>-5.4 (22.7)</p></td><td style="vertical-align:top"><p>-29.3 (22.9)</p></td></tr><tr><td style="vertical-align:top"><p>Fatigue/Mood score</p></td><td style="vertical-align:top"><p>-1.8 (23.3)</p></td><td style="vertical-align:top"><p>-13.0 (23.1)</p></td></tr><tr><td style="vertical-align:top"><p>Fear/Shame score</p></td><td style="vertical-align:top"><p>-9.0 (24.0)</p></td><td style="vertical-align:top"><p>-18.8 (23.7)</p></td></tr><tr><td style="vertical-align:top"><p>Nutrition score</p></td><td style="vertical-align:top"><p>0.5 (22.5)</p></td><td style="vertical-align:top"><p>-17.0 (22.3)</p></td></tr></tbody></table><p><sub>Note: AE-QoL= Angioedema Quality of Life; LS=least squares; SD=standard deviation.</sub></p><p><sub>a Lower scores indicate lower impairment (or better health-related quality of life).</sub></p><p>&nbsp;</p><p><em>HELP study extension</em></p><p>Long-term safety and efficacy of TAKHZYRO for prophylaxis to prevent HAE attacks was evaluated in an open-label HELP study extension.</p><p>A total of 212 adult and adolescent subjects with symptomatic type I or II HAE received at least one dose of lanadelumab in this study, including 109 subjects who entered as rollover subjects from the HELP study and 103 new or non-rollover subjects (including 19 subjects from Phase1b study) who had an historical baseline attack rate of &ge;1 attack per 12 weeks Subjects were allowed to initiate</p><p>self-administration after receiving the first 2 doses from a health care professional in clinic and completing appropriate training. Interim analysis indicates that the effect was sustained up to one year of treatment.</p><p><u>Paediatric population</u></p><p>The European Medicines Agency has deferred the obligation to submit the results of studies with TAKHZYRO in one or more subsets of the paediatric population in the prevention of hereditary angioedema attacks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The single and multiple dose pharmacokinetics of lanadelumab have been studied in patients with HAE. Pharmacokinetics of lanadelumab showed linear dose-exposure response with doses up to 400 mg and reproducible exposure following subcutaneous administration up to 12 months. The</p><p>absolute bioavailability of lanadelumab after subcutaneous administration has not been determined. In the HELP study, patients treated with 300 mg q2 wks presented mean (SD) area under the curve over the dosing interval at steady-state (AUCtau,ss), maximum concentration at steady-state (Cmax,ss) and minimum concentration at steady-state (Cmin,ss) of 408 &micro;g*day/ml (138), 34.4 &micro;g/mL (11.2), and</p><p>25.4 &micro;g/mL (9.18), respectively. The anticipated time to reach steady state concentration was approximately 70 days.</p><p><u>Absorption</u></p><p>Following SC administration, the time to maximum concentration is approximately 5 days. The site of SC injection (thigh, arm, or abdomen) and self-administration did not affect the absorption of lanadelumab.</p><p><u>Distribution</u></p><p>The mean (SD) volume of distribution of lanadelumab in patients with HAE is 14.5 litres (4.53). Lanadelumab is a therapeutic monoclonal antibody and is not expected to bind to plasma proteins.</p><p><u>Elimination</u></p><p>Lanadelumab has a mean (SD) total body clearance of 0.0297 L/h (0.0124) and a terminal elimination half-life of approximately 14 days.</p><p><u>Special populations</u></p><p>No dedicated studies have been conducted to evaluate the pharmacokinetics of lanadelumab in special patient populations including gender, age, pregnant women or the presence of renal or hepatic impairment.</p><p>In a population pharmacokinetic analysis, after correcting for body weight, no influence of gender or age (12 to 75 years) was apparent on the clearance or volume of distribution of lanadelumab.</p><p>Although body weight was identified as an important covariate describing the variability of clearance, a 300 mg q2wks dose regimen provided sufficient exposure for the indication (see section 5.1).</p><p><u>Renal and hepatic impairment</u></p><p>As IgG monoclonal antibodies are mainly eliminated via intracellular catabolism, renal impairment or hepatic impairment is not expected to influence clearance of lanadelumab.</p><p>Accordingly, in a population pharmacokinetic analysis, renal impairment (estimated GFR:</p><p>60 to 89 ml/min/1.73 m2 [mild, N=98] and 30 to 59 ml/min/1.73m2 [moderate, N=9]) had no effect on the clearance or volume of distribution of lanadelumab.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In repeat-dose studies evaluating once weekly SC injection in both rats (up to 28 days) and cynomolgus monkeys (up to 6 months) lanadelumab was well-tolerated at doses of up to and including 50 mg/kg (highest dose tested) with no organs of toxicity identified. Exposures in cynomolgus monkeys following 6 months of administration were approximately 23-fold greater than that noted at 300 mg q2 wks based on AUC.</p><p>Lanadelumab is not expected to interact directly with DNA or other chromosomal material, as it is made up entirely of naturally occurring amino acids and contains no inorganic or synthetic linkers or other nonprotein portions; therefore no genotoxicity evaluation has been conducted.</p><p>Carcinogenicity has not been evaluated in animals as based on the weight of evidence approach, lanadelumab is considered to have a low risk for carcinogenicity.</p><p>The effects of lanadelumab on fertility were evaluated in sexually mature cynomolgus monkeys. In a 13-week study, once weekly SC administration of lanadelumab had no effects on male or female fertility at doses of 10 or 50 mg/kg (highest dose tested). Exposures in sexually mature cynomolgus monkeys in the fertility study were approximately 20-and 22-fold greater than that noted at</p><p>300 mg q2 wks based on Cmax and AUC, respectively.</p><p>In the ePPND study in pregnant cynomolgus monkeys administered once weekly doses of 10 or 50 mg/kg (highest dose tested), there were no lanadelumab-related effects on pregnancy and parturition,</p><p>embryo-foetal development, survival, growth, and/or postnatal development of offspring. Exposures in the ePPND study were approximately 32-fold greater than that noted at 300 mg q2 wks based on AUC.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="1" cellspacing="0" cellpadding="0"><tbody><tr><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Name of Excipient</strong></p></td><td style="vertical-align:top"><p><strong>&nbsp;</strong></p><p><strong>Quantity per vial (per 2.0 mL</strong><strong>1)</strong></p></td></tr><tr><td style="vertical-align:top"><p>Disodium phosphate dihydrate</p></td><td style="vertical-align:top"><p>10.6 mg</p></td></tr><tr><td style="vertical-align:top"><p>Citric acid monohydrate</p></td><td style="vertical-align:top"><p>8.2 mg</p></td></tr><tr><td style="vertical-align:top"><p>L-Histidine</p></td><td style="vertical-align:top"><p>15.6 mg</p></td></tr><tr><td style="vertical-align:top"><p>Sodium chloride</p></td><td style="vertical-align:top"><p>10.6 mg</p></td></tr><tr><td style="vertical-align:top"><p>Polysorbate 80</p></td><td style="vertical-align:top"><p>0.2 mg</p></td></tr><tr><td style="vertical-align:top"><p>Water for injection</p></td><td style="vertical-align:top"><p>q.s.2 to 2.0 mL</p></td></tr></tbody></table><p><sub>1Quantities are nominal based on targets established for drug substance manufacturing</sub></p><p><sub>2 q.s.=Quantity Sufficient</sub></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                2 years.
Chemical and physical in-use stability has been demonstrated for 2 hours at 25°C and for 8 hours at 2°C to 8°C. From a microbiological point of view, unless the method of preparation precludes the risks of microbial contamination, the product should be used immediately. If not used immediately, in-use storage times and conditions are the responsibility of the user. TAKHZYRO should be administered within 2 hours of preparing the dosing syringe. If not administered immediately after preparation, the syringe may be stored in the refrigerator (2C to 8C), protected from light and administered within 8 hours.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store in a refrigerator (2&deg;C to 8&deg;C). Do not freeze.</p><p>Keep vial in the outer carton in order to protect from light.</p><p>Vials may be stored below 25&deg;C for a single period of 14 days, but not beyond the expiry date. Do not return TAKHZYRO to refrigerated storage after storage at room temperature.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>2 ml of solution in a vial (type I glass) with a coated butyl rubber stopper and an aluminium seal with violet flip-off cap. Pack size of 1 vial.</p><p>Each pack also contains the following items:</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Empty 3 ml syringe</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 18G vial access needle</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 27G x &frac12; inch (0.4 x 13 mm) injection needle</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lanadelumab is provided in single use vials.</p><p>Before use, each vial should be visually inspected for appearance. The solution should be clear or slightly yellow. Solutions that are discoloured or contain particles should not be used.</p><p>Avoid vigorous agitation.</p><p><u>Administration steps</u></p><p>Using aseptic technique, withdraw the prescribed dose of TAKHZYRO from the vial into the syringe using an 18 gauge needle.</p><p>Change the needle on the syringe to a 27 gauge needle or other needle suitable for SC injection. Inject TAKHZYRO subcutaneously into the abdomen, thigh, or upper arm (see section 4.2).</p><p>Discard the vial with any unused contents.</p><p>Any unused medicinal product or waste material should be disposed of in accordance with local requirements.</p><p>All needles and syringes should be disposed of in a sharps container.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Holder:
Shire Pharmaceuticals Ireland Limited Blocks 2 & 3 Miesian Plaza
50-58 Baggot Street Lower Dublin 2
Ireland
Tel: +44(0)1256 894 959
E-mail: medinfoEMEA@shire.com

Manufacturer:
Catalent Indiana, LLC (formerly Cook Pharmica LLC) 1300 South Patterson Drive Bloomington, IN 47403 United States of America


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Jun-2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>